Matthias Seifert

Matthias Seifert

Auto-generated profile, based on publicly available information

Matthias Seifert

Institute of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2021 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
SLStefanie Lesch
Stefanie Lesch
VBViktoria Blumenberg
Viktoria Blumenberg
SSStefan Stoiber
Stefan Stoiber
AGAdrian Gottschlich
Adrian Gottschlich
JOJustyna Ogonek
Justyna Ogonek
SKSebastian Kobold
Sebastian Kobold

13 March 2023 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
AGAdrian Gottschlich
Adrian Gottschlich
MTMoritz Thomas
Moritz Thomas
RGRuth Grünmeier
Ruth Grünmeier
SLStefanie Lesch
Stefanie Lesch
LRLisa Rohrbacher
Lisa Rohrbacher
SKSebastian Kobold
Sebastian Kobold

11 June 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
BCBruno Cadilha
Bruno Cadilha
MBMohamed-Reda Benmebarek
Mohamed-Reda Benmebarek
KDKlara Dorman
Klara Dorman
AOArman Oner
Arman Oner
TLTheo Lorenzini
Theo Lorenzini
SKSebastian Kobold
Sebastian Kobold
CAR T cell therapy remains ineffective in solid tumors, due largely to poor infiltration and T cell suppression at the tumor site. T regulatory (Treg) cells suppress the immune response via inhibitory factors such as transforming growth factor–β (TGF-β). Treg cells expressing the C-C chemokine receptor 8 (CCR8) have been associated with poor prognosis in solid tumors. We postulated that CCR8 could be exploited to redirect effector T cells to the tumor site while a dominant-negative TGF-β receptor 2 (DNR) can simultaneously shield them from TGF-β. We identified that CCL1 from activated T cells potentiates a feedback loop for CCR8+ T cell recruitment to the tumor site. This sustained and improved infiltration of engineered T cells synergized with TGF-β shielding for improved therapeutic efficacy. Our results demonstrate that addition of CCR8 and DNR into CAR T cells can render them effective in solid tumors.


24 May 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
EWElias Walter
Elias Walter
FVFranziska Vielmuth
Franziska Vielmuth
MWMarie-Therès Wanuske
Marie-Therès Wanuske
MSMatthias Seifert
Matthias Seifert
RPRobert Pollmann
Robert Pollmann
JWJens Waschke
Jens Waschke
Pemphigus is an autoimmune dermatosis in which mucocutaneous blisters are induced primarily by autoantibodies against Desmoglein (Dsg) 1 and 3. Pemphigus vulgaris (PV) usually is associated with autoantibodies against Dsg3 whereas pemphigus foliaceus (PF) patients present autoantibodies against Dsg1. Several signaling pathways were proposed to cause loss of keratinocyte adhesion. However, relevance of different signaling pathways and role of Dsg1 and 3 to trigger signaling are not fully understood. Here, we show that Ca2+ chelation reduced PV-IgG- and PF-IgG-mediated loss of HaCaT keratinocyte cohesion whereas EGFR inhibition did not inhibit effects of PF-IgG. PV-IgG activated EGFR in a Src-dependent manner whereas both PV-IgG and PF-IgG caused Ca2+ influx independent of EGFR. ERK activation was Src-dependent in response to PV-IgG but not PF-IgG. To delineate the roles of Dsg isoforms to trigger signaling pathways, Dsg3- and Dsg2-deficient HaCaT keratinocyte cell lines were generated using CRISPR/Cas9. Dsg3- but not Dsg2-deficient cells were protected against PV-IgG-induced loss of cell adhesion. Ca2+ influx and ERK activation in response to PF-IgG were preserved in both cell lines.

4 July 2023 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
TLTheo Lorenzini
Theo Lorenzini
BCBruno Cadilha
Bruno Cadilha
HOHannah Obeck
Hannah Obeck
MBMohamed-Reda Benmebarek
Mohamed-Reda Benmebarek
FMFlorian Märkl
Florian Märkl
SKSebastian Kobold
Sebastian Kobold
Background: In many situations, the therapeutic efficacy of CAR T cells is limited due to immune suppression and poor persistence. Immunostimulatory fusion protein (IFP) constructs have been advanced as a tool to convert suppressive signals into stimulation and thus promote the persistence of T cells, but no universal IFP design has been established so far. We now took advantage of a PD-1-CD28 IFP as a clinically relevant structure to define key determinants of IFP activity. Methods: We compared different PD-1-CD28 IFP variants in a human leukemia model to assess the impact of distinctive design choices on CAR T cell performance in vitro and a xenograft mouse model. Results: We observed that IFP constructs that putatively exceed the extracellular length of PD-1 induce T-cell response without CAR target recognition, rendering them unsuitable for tumour-specific therapy. IFP variants with physiological PD-1 length ameliorated CAR T cell effector function and proliferation in response to PD-L1+ tumour cells in vitro and prolonged survival in vivo. Transmembrane or extracellular CD28 domains were found to be replaceable by corresponding PD-1 domains for in vivo efficacy. Conclusion: PD-1-CD28 IFP constructs must mimic the physiological interaction of PD-1 with PD-L1 to retain selectivity and mediate CAR-conditional therapeutic activity.